These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 24249759)

  • 1. Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes.
    Ottney A
    Am J Health Syst Pharm; 2013 Dec; 70(23):2097-103. PubMed ID: 24249759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy.
    Derosa G; Maffioli P
    Curr Clin Pharmacol; 2012 Aug; 7(3):214-28. PubMed ID: 22432846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.
    Madsbad S
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):463-77. PubMed ID: 19748064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.
    Hayes MR; Kanoski SE; Alhadeff AL; Grill HJ
    Obesity (Silver Spring); 2011 Jul; 19(7):1342-9. PubMed ID: 21415845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
    Sun F; Chai S; Li L; Yu K; Yang Z; Wu S; Zhang Y; Ji L; Zhan S
    J Diabetes Res; 2015; 2015():157201. PubMed ID: 25688373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis.
    Sun F; Yu K; Yang Z; Wu S; Zhang Y; Shi L; Ji L; Zhan S
    Exp Diabetes Res; 2012; 2012():230624. PubMed ID: 23365557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.
    Horowitz M; Aroda VR; Han J; Hardy E; Rayner CK
    Diabetes Obes Metab; 2017 May; 19(5):672-681. PubMed ID: 28058769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging GLP-1 receptor agonists.
    Lund A; Knop FK; Vilsbøll T
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice.
    Sauer N; Reining F; Schulze Zur Wiesch C; Burkhardt T; Aberle J
    Horm Metab Res; 2015 Jul; 47(8):560-4. PubMed ID: 25230325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin hormones and the satiation signal.
    Holst JJ
    Int J Obes (Lond); 2013 Sep; 37(9):1161-8. PubMed ID: 23295502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in acute anorectic effects of long-acting GLP-1 receptor agonists in rats.
    Sisley S; Smith K; Sandoval DA; Seeley RJ
    Peptides; 2014 Aug; 58():1-6. PubMed ID: 24879927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.
    Gallwitz B
    Drugs; 2011 Sep; 71(13):1675-88. PubMed ID: 21902291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
    Peterson G
    Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
    Esposito K; Mosca C; Brancario C; Chiodini P; Ceriello A; Giugliano D
    Curr Med Res Opin; 2011 Aug; 27(8):1519-28. PubMed ID: 21663496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.